ReviewAnnals of the rheumatic diseases2005
Psoriasis treatment: current and emerging directed therapies.
Review in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.Annals of the rheumatic diseases · 2007Trial
- Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.International journal of dermatology · 2026Article
- Selenium-functionalized hyaluronic acid dissolvable microneedle patch synergistic herbal shikonin-loaded tetrahedral framework nucleic acids for psoriasis therapy.Materials today. Bio · 2025Article
- Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis.International journal of molecular sciences · 2025Article
- Article
- Article
- Psoriasis treatment using minimally manipulated umbilical cord-derived mesenchymal stem cells: A case report.World journal of clinical cases · 2021Article
- Weighted gene coexpression network and experimental analyses identify lncRNA SPRR2C as a regulator of the IL-22-stimulated HaCaT cell phenotype through the miR-330/STAT1/S100A7 axis.Cell death & disease · 2021Article
- Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis.Clinical, cosmetic and investigational dermatology · 2021Review
- Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: AnFrontiers in chemistry · 2020Article
- Guselkumab for the treatment of psoriasis - evidence to date.Drugs in context · 2019Review
- Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience.Therapeutic advances in chronic disease · 2018Review
- Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action.International journal of nanomedicine · 2017Article
- Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions.Dermatology research and practice · 2016Article
- Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and -9 in psoriatic plaques.Experimental and therapeutic medicine · 2015Article
- Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis.Clinical reviews in allergy & immunology · 2012Article
- Treating psoriasis with adalimumab.Therapeutics and clinical risk management · 2008Article
- Biological markers in the etiology of psoriasis: Targeted treatment options.Biologics : targets & therapy · 2007Article
- A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.American journal of human genetics · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quality of life studies in patients with cutaneous psoriasis attest to its significant impact on day to day activities and personal social interactions. Up to 40% of patients with psoriasis may develop psoriatic arthritis, usually within 5-10 years after onset of the cutaneous disease, heightening quality of life issues. These data have prompted an increased awareness and interest in more aggressive management of psoriasis; coupled with a better understanding of immunopathogenesis, this has led to the development of new agents targeting specific cells and molecules involved in the development and maintenance of psoriatic plaques. Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. This review concentrates on new biological agents, focusing on the three agents approved for psoriasis within the past 18 months (alefacept, efalizumab, and etanercept). Phase II and III trial data on other agents in development (adalimumab and infliximab) are also presented. Surveys show many patients want to be treated more aggressively. It is hoped that the introduction of new agents that are more targeted and that hold the promise of fewer side effects will cause patients and their physicians to reconsider systemic treatment and, as a consequence, stimulate other patients to reconsider treatment for psoriasis. Close cooperation between dermatologists and rheumatologists, particularly in the area of psoriatic joint disease, will enhance these considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.